

I hereby certify that this paper is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on October 3, 2002.

Carole J. Smith
Carole J. Smith

October 3, 2002
Date of Signature

PATENT
Case 51882 JSM1
RECEIVED
OCT 09 2002
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of :

Richard HORUK :

Serial No. 09/915,411 :

Group Art Unit: 1615

Filed: July 25, 2001 :

Examiner: Not Yet Known

For Non-Peptide CCR1 Receptor Antagonists in Combination with Cyclosporin A for the Treatment of Heart Transplant Rejection

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

TRANSMITTAL LETTER

Transmitted herewith for filing in the above-entitled patent application is the following.

1. Supplemental Information Disclosure Statement
2. 1449 Form with References
3. Return postcard

Deposit Fee Authorization

Any fees which may be required should be charged to Deposit Account No. 02-2117. This is not, however, an authorization to pay the issue fee. A duplicate of this document is enclosed.

Respectfully submitted,

Neil G. Miyamoto

Neil G. Miyamoto, Ph.D.
Patent Agent for Applicants
Reg. No. 50,370

Berlex Biosciences
2600 Hilltop Drive
P.O. Box 4099
Richmond, CA 94804-0099
(510) 669-4699 Telephone
(510) 262-7095 Facsimile

Date: October 3, 2002



PATENT
Case 51882AUSM1

RECEIVED
OCT 09 2002
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In r Application of
Richard HORUK

:

Serial No. 09/915,411

: Group Art Unit 1615

Filed July 25, 2001

: Examiner Not Yet Known

Title: NON-PEPTIDE CCR1 RECEPTOR ANTAGONISTS IN COMBINATION WITH
CYCLOSPORIN A FOR THE TREATMENT OF HEART TRANSPLANT REJECTION

#3
JM
10/11/02

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97 AND
STATEMENT UNDER 37 CFR 1.97(e)**

In accordance with Applicants' duty of disclosure under 37 CFR 1.56(a), Applicants direct the attention of the Office to the following documents, which are listed on attached modified Form PTO-1449 (1 page). These documents may be material to the examination of the above-identified patent application filed herewith.

1. Patent Cooperation Treaty Published Patent Application 99 40061 (Kath *et al.*), which discloses dihydroxyhexanoic acid derivatives useful to treat inflammation and other immune disorders.
2. Patent Cooperation Treaty Published Patent Application 99 37619 (Luly *et al.*), which discloses organic compound chemokine receptor antagonists and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation.
3. Patent Cooperation Treaty Published Patent Application 99 37617 (Schwender *et al.*), which discloses organic compound chemokine receptor antagonists and a method of treating a subject with a disease associated with aberrant leukocyte recruitment and/or activation.
4. Patent Cooperation Treaty Published Patent Application 99 37651 (Luly *et al.*), which discloses organic compound chemokine receptor antagonists and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation.
5. Patent Cooperation Treaty Published Patent Application 98 38167 (Brown *et al.*), which discloses heteroaryl-hexanoic acid amide derivatives useful to treat inflammation and other disorders.

Copies of the above-listed documents are provided herewith.

Applicants make no admission by the citation of these documents that any of them necessarily constitute "prior art" to the instant application.

The Examiner is respectfully requested to consider these documents and to indicate that this has been done by initialing and returning a copy of the modified Form PTO-1449 filed herewith to the Applicants, in accordance with MPEP 609.

The undersigned Agent for Applicants hereby states under 37 CFR 1.97(e) that each of the above-listed references was cited in the International Search Report for WO 02/09762, which is the counterpart foreign application to the above-identified patent application, not more than three months prior to the filing of the Supplemental Information Disclosure Statement.

Respectfully submitted,



Neil G. Miyamoto, Ph.D.
Agent for Applicants
Registration No. 50,370

Berlex Biosciences
2600 Hilltop Drive
P.O. Box 4099
Richmond, California 94804-0099
Tel: 510.669.4699
Fax: 510.262.7095
E-mail: neil_miyamoto@berlex.com
Date: October 1, 2002

RECEIVED

OCT 09 2002
TECH CENTER 1600/2900

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	ATTY. DOCKET NO. 51882AUSM1	SERIAL NO. 09/915,411
	APPLICANT(S) Richard HORUK	
	FILING DATE July 25, 2001	GROUP 1615



U.S. PATENT DOCUMENTS						
Initial		Document Number	Date	Name	Class/ Subclass	Filing Date

FOREIGN PATENT DOCUMENTS						
Initial		Document Number	Date	Country	Translation	
					Yes	No
	01	WO 99/40061	07/1999	PCT	X	
	02	WO 99/37619	07/1999	PCT	X	
	03	WO 99/37617	07/1999	PCT	X	
	04	WO 99/37651	07/1999	PCT	X	
	05	WO 98/38167	09/1998	PCT	X	

OTHER DOCUMENTS (Include Author, Title, Date, Pertinent Pages, etc.)						

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	